EGFR mutated NSCLC
![Johnson & Johnson, Rybrevant, EGFR mutated NSCLC, Tagrisso, Osimirtinib, Clinical trial results, AstraZeneca](https://pharmtales.com/wp-content/uploads/2023/09/JJs-Rybrevant-beats-chemo-in-lung-cancer-patients-who-failed-Tagrisso.jpg)
J&J’s Rybrevant Beats Chemo In Lung Cancer Patients Who Failed Tagrisso
Anika Sharma
The medical community buzzed with anticipation when Johnson & Johnson (J&J) released information about Rybrevant, their latest drug venture into ...